This clinical trial is for men and women with meningioma. Currently available treatments are not effective in treating patients with this disease. Therefore, there is a need to find treatments that work for patients with meningoioma.
This phase II trial studies how well vismodegib and focal adhesion kinase (FAK) inhibitor GSK2256098 work in treating patients with meningiomas that may have gotten bigger or grew back after treatment. Vismodegib and FAK inhibitor GSK2256098 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Eligible patients will be randomized (by chance) to one of each arm (vismodegib or GSK2256098). There is no placebo (blank pill). Patients will continue on treatment as long as they are responding to therapy and not experiencing unacceptable side effects.